ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

NCI Directory Delayed

January 27, 1984

President’s Cancer Panel: NCI’s Approach “Paying Off,” Thompson Tells Cancer Panel

June 1, 2001

AIDS Drug Discovery Groups RFA Draws 20 Applications

May 9, 1986

“Evolving Concept” Looks At Appropriate Early Decision Making In Patient Management

September 28, 1984

President Signs Interim Money Bill; NCI At $725 Million

July 4, 1975

NCI “Rescues” 31 Grants From Other Institutes, Funds Them at 41.6 Million; Scores Were 148-270

August 9, 1974